AgingResearch.NewsJoin free

Gasherbrum Bio

Part of Structure Therapeutics

CompanyUnited States

Gasherbrum Bio develops one asset, in phase 3 (aleniglipron in obesity). Mostly small molecule acting on GLP1R; based in the United States.

1
Asset
Furthest stage
Phase 3
5
Trials
2
Signals

Pipeline

1

  • aleniglipron

    Oral small molecule GLP-1 receptor agonist for chronic weight management

    Phase 3, Small molecule, GLP1R, obesity, overweight

Full company profiles: pipeline, trials, funding and people.

See Pro

In the full profile

  • Evidence behind the mechanisms2
  • Trials5
  • Signals11
  • Similar companies6

Intelligence